Vanucizumab (Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985) |
| Katalog-Nr.GC70111 |
Vanucizumab is a novel bispecific IgG1 monoclonal antibody that can simultaneously block the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their receptors. Vanucizumab has anti-angiogenic and anticancer effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1448221-05-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for Vanucizumab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Vanucizumab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *